TIL INSTIL BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, INSTIL BIO INC reported revenue of n/a, net income of −$4.30M and diluted EPS of −$0.63; for the fiscal year ended December 2025 revenue was n/a.
TIL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$78.6M, net income −$71.4M (margin n/a), EPS −$10.70
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$73.5M, net income −$74.1M (margin n/a), EPS −$11.39
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$159M, net income −$156M (margin n/a), EPS −$24.00
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$226M, net income −$223M (margin n/a), EPS −$34.46
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$156M, net income −$157M (margin n/a), EPS −$1.48
TIL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.30M, EPS −$0.63
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.20M, EPS −$0.62
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$8.19M, EPS −$1.13
- Quarter ended Sep 30, 2025: revenue n/a, net income −$13.6M, EPS −$2.01
- Quarter ended Jun 30, 2025: revenue n/a, net income −$21.4M, EPS −$3.24
- Quarter ended Mar 31, 2025: revenue n/a, net income −$28.2M, EPS −$4.32
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$11.9M, EPS −$1.82
- Quarter ended Sep 30, 2024: revenue n/a, net income −$23.0M, EPS −$3.54
- Quarter ended Jun 30, 2024: revenue n/a, net income −$14.9M, EPS −$2.29
- Quarter ended Mar 31, 2024: revenue n/a, net income −$24.3M, EPS −$3.74
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$12.9M, EPS −$1.99
- Quarter ended Sep 30, 2023: revenue n/a, net income −$67.4M, EPS −$10.37
- Quarter ended Jun 30, 2023: revenue n/a, net income −$18.7M, EPS −$2.87
- Quarter ended Mar 31, 2023: revenue n/a, net income −$57.1M, EPS −$8.77
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$53.8M, EPS −$33.15
- Quarter ended Sep 30, 2022: revenue n/a, net income −$56.2M, EPS −$0.43
- Quarter ended Jun 30, 2022: revenue n/a, net income −$59.0M, EPS −$0.46
- Quarter ended Mar 31, 2022: revenue n/a, net income −$54.1M, EPS −$0.42
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$55.4M, EPS −$0.22
- Quarter ended Sep 30, 2021: revenue $0, net income −$43.0M, EPS −$0.33
TIL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$36.6M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$55.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$82.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$180M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$122M, share buybacks n/a
TIL balance sheet
- Jun 30, 2026: cash $5.54M, total assets $198M, total liabilities $90.3M, shareholders' equity $107M
- Mar 31, 2026: cash $5.02M, total assets $200M, total liabilities $89.7M, shareholders' equity $111M
- Dec 31, 2025: cash $6.64M, total assets $204M, total liabilities $89.7M, shareholders' equity $114M
- Sep 30, 2025: cash $5.80M, total assets $212M, total liabilities $91.3M, shareholders' equity $120M
- Jun 30, 2025: cash $7.69M, total assets $231M, total liabilities $99.3M, shareholders' equity $132M
- Mar 31, 2025: cash $15.4M, total assets $237M, total liabilities $92.5M, shareholders' equity $145M
- Dec 31, 2024: cash $8.81M, total assets $264M, total liabilities $94.1M, shareholders' equity $169M
- Sep 30, 2024: cash $6.66M, total assets $273M, total liabilities $96.2M, shareholders' equity $176M
Is TIL profitable?
No. INSTIL BIO INC lost $30.3M over the last four quarters.
What is TIL's EPS?
Diluted earnings per share over the last four quarters were −$4.39; −$0.63 in the latest quarter.